← Back to Clinical Trials
Recruiting NCT07606495

NCT07606495 Impact on Prognosis of Increased Sleep Quality Obtained by Personalized Night-time Nursing Care in Critically Ill Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07606495
Status Recruiting
Phase —
Sponsor Poitiers University Hospital
Condition Intensive Care Unit (ICU)
Study Type INTERVENTIONAL
Enrollment 460 participants
Start Date 2026-09-16
Primary Completion 2028-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Sleepscan deviceSleep-guided nursing care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 460 participants in total. It began in 2026-09-16 with a primary completion date of 2028-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Sleep disturbances are common among intensive care unit (ICU) patients and have been associated with difficult weaning from invasive mechanical ventilation, with an increased risk of endotracheal intubation. Other studies have reported associations between sleep disturbances and prolonged ICU length of stay or the occurrence of delirium. Among the factors contributing to sleep impairment, nighttime care interventions have been identified as a major cause. The management of sleep disorders in the ICU remains complex and often disappointing, and no pharmacological treatment is currently formally recommended. Very recently, a considerable improvement of sleep quantity (+50%) and quality (doubling of deep sleep quantity) has been reported by reorganizing nighttime nursing care according to patients' sleep cycles, using a sleep monitoring medical device. The objective of this study is to quantify the impact of a better sleep on prognosis. Sleep will be improved using sleep-guided nursing care during nighttime thanks to a real-time sleep monitor (Sleepscan°). The primary endpoint is the proportion of patients requiring invasive mechanical ventilation or who have died at day 7 after inclusion. The main secondary outcomes include the duration of ICU stay, the number of delirium free-days, the score at a discomfort scale, the score at a post-traumatic stress disorder scale at ICU discharge. Intensive care unit-related costs will be assessed. A multi-sites, prospective, randomized, open-label, superiority trial with two parallel arms will be conducted. Awake and conscious patients without continuous sedation, regardless of ventilatory support, with no indication for urgent intubation (\<12 hours) and with an expected ICU length of stay greater than 48 hours will be included. The intervention will consist of sleep-guided nighttime nursing care using the Sleepscan monitor from 7:00 p.m. to 7:00 a.m., every night until ICU discharge or day 7. Sleep-guided nursing care consist in postponing non urgent care (such as temperature measurement…) and avoiding entering the room when patients are asleep. Otherwise, when patients are awake, instructions are to go for all care, to cluster and anticipate nursing care and perform comfort care. In the control group, sleep will also be recorded using the same device but the tablet will not display the patient's sleep (or awake) status, and nighttime nursing care will be performed according to usual practice and independently of patients' sleep cycles. Based on our preliminary data and previous studies, it has been estimated that 230 patients per group will be required to detect a reduction in the proportion of patients intubated or deceased at day 7 from 20% in the control group to 10% in the intervention group. The intention-to-treat analysis population will include all randomized patients. Demonstrating an improvement in patient prognosis through enhanced sleep quality would represent a major advancement for intensive care medicine. Reducing the need for invasive mechanical ventilation may lead to shorter ICU stays, lower mortality, fewer post-ICU complications, and reduced hospital costs. Demonstrating an improvement in patient prognosis through enhanced sleep quality would represent a major advancement for intensive care medicine. Reducing the need for invasive mechanical ventilation and the incidence of delirium may lead to shorter ICU stays, lower mortality, fewer post-ICU complications, and reduced hospital costs.

Eligibility Criteria

Inclusion Criteria: * Patients aged 18 years or older admitted to an intensive care unit * Conscious patients with a Richmond Agitation-Sedation Scale (RASS) score between -2 and +1 * Patients without continuous sedation, regardless of ventilatory support * No indication for urgent intubation (\<12 hours) * Informed consent from the relatives or the patient himself Exclusion Criteria: * Brain tumor or neuropsychiatric disorders affecting sleep * Amission for stroke or epilepsy * Administration of sleep-modifying medication within 24 hours prior to randomization * Patients with skin lesions around the central right and left areas preclunding the placement of the electrodes * Patients with expected ICU length of stay less than 48 hours * Patients with limitation or withdrawal of life-sustaining therapies * Patients already included in the study during a previous hospitalization * Patients under law protection (guardianship, conservatorship, or judicial protective measures) * People under protection (minors, persons deprived of liberty by a judicial or administrative decision, patients in emergency situations)

Contact & Investigator

Central Contact

Xavier DROUOT

✉ xavier.drouot@chu-poitiers.fr

📞 +33549444444

Frequently Asked Questions

Who can join the NCT07606495 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Intensive Care Unit (ICU). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07606495 currently recruiting?

Yes, NCT07606495 is actively recruiting participants. Contact the research team at xavier.drouot@chu-poitiers.fr for enrollment information.

Where is the NCT07606495 trial being conducted?

This trial is being conducted at La Roche-sur-Yon, France, La Rochelle, France, Le Mans, France, Poitiers, France and 3 additional locations.

Who is sponsoring the NCT07606495 clinical trial?

NCT07606495 is sponsored by Poitiers University Hospital. The trial plans to enroll 460 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology